XML 65 R47.htm IDEA: XBRL DOCUMENT v3.19.1
Omeclamox®-Pak, Ethyol®, RediTrex®, Totect® and Vibativ® - Narrative (Details) - USD ($)
shares in Thousands
1 Months Ended 12 Months Ended
Oct. 29, 2013
Nov. 30, 2016
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Business Acquisition [Line Items]          
Payments for asset acquisitions     $ 2,300,000    
Revenue from Contract with Customer, Excluding Assessed Tax     40,200,832 $ 40,376,563 $ 32,478,185
Other revenue, potential upfront payment related to product sales     4,600,000    
Payments to acquire businesses     20,000,000 0 0
Amended International Agreement | Pernix Therapeutics          
Business Acquisition [Line Items]          
Other revenue, potential upfront payment related to product sales $ 4,000,000.0   2,300,000    
Omeclamox-Pak          
Business Acquisition [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax     600,000 1,800,000  
Ethyol | Minimum          
Business Acquisition [Line Items]          
Royalty payments based on percentage over gross profits 30.00%        
Ethyol | Maximum          
Business Acquisition [Line Items]          
Royalty payments based on percentage over gross profits 50.00%        
Methotrexate          
Business Acquisition [Line Items]          
Payments to acquire businesses   $ 100,000      
Liabilities incurred   $ 900,000      
Stock issued during period, acquisitions     1,100,000 1,300,000  
Omeclamox-Pak          
Business Acquisition [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax     623,297 1,761,868 2,536,027
Ethyol          
Business Acquisition [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax     $ 10,545,906 $ 10,835,038 $ 838,386
Restricted Stock | Methotrexate          
Business Acquisition [Line Items]          
Stock issued during period, acquisitions (in shares)   180